FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907376823> ?p ?o ?g. }

• W2907376823 endingPage "52" @default.
• W2907376823 startingPage "42" @default.
• W2907376823 abstract "Summary About 30% of all Hodgkin lymphoma ( HL ) patients are ≥60 years old. As lenalidomide has promising single agent activity in multiple relapsed HL , we replaced bleomycin in ABVD with lenalidomide in this phase‐I trial. Patients aged ≥60 years with early‐unfavourable‐ or advanced‐stage HL (Eastern Cooperative Oncology Group performance status ≤2, Cumulative Illness Rating Scale for Geriatrics score 0–7) received 4–8 cycles of AVD (doxorubicin, vinblastine, dacarbazine) and lenalidomide in escalation with overdose control. Dose‐limiting toxicities ( DLT s) included thromboembolism ≥grade 2, severe haematological toxicity, neutropenic fever and prolonged therapy delay. Twenty‐five patients with a median age of 68 years were included, 68% had advanced‐stage HL . A pre‐defined stopping criterion for dose escalation after DLT evaluation of 20/24 patients suggested a recommended phase II dose ( RPTD ) of 20 mg. DLT s occurred in 10/24 evaluable patients, all treated with ≥20 mg, however, median relative dose intensity was 97% (interquartile range 49–104%). Grade 3 or higher toxicities occurred in all 22 patients at ≥20 mg lenalidomide but no treatment‐related deaths occurred. Overall response rate was 80% for all patients (20/25) and 86% (19/22) at ≥20 mg lenalidomide. Three‐year estimates for progression‐free survival and OS were 69·7% (95% CI : 50·3–89·1%) and 83·8% (95%‐ CI : 69·3–98·4%), respectively. In conclusion, AVD with lenalidomide 20 mg is feasible and highly effective in older HL patients." @default.
• W2907376823 created "2019-01-11" @default.
• W2907376823 creator A5008778599 @default.
• W2907376823 creator A5014979722 @default.
• W2907376823 creator A5017330007 @default.
• W2907376823 creator A5040054777 @default.
• W2907376823 creator A5054847681 @default.
• W2907376823 creator A5055488306 @default.
• W2907376823 creator A5057387418 @default.
• W2907376823 creator A5059148672 @default.
• W2907376823 creator A5060299777 @default.
• W2907376823 creator A5060345625 @default.
• W2907376823 creator A5061498879 @default.
• W2907376823 creator A5064132655 @default.
• W2907376823 creator A5076460303 @default.
• W2907376823 creator A5077518022 @default.
• W2907376823 date "2018-12-28" @default.
• W2907376823 modified "2023-10-18" @default.
• W2907376823 title "Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (<scp>GHSG</scp>) phase‐I trial" @default.
• W2907376823 cites W1975834243 @default.
• W2907376823 cites W1977273659 @default.
• W2907376823 cites W1978296090 @default.
• W2907376823 cites W2002649801 @default.
• W2907376823 cites W2018849750 @default.
• W2907376823 cites W2031593269 @default.
• W2907376823 cites W2036583226 @default.
• W2907376823 cites W2045985885 @default.
• W2907376823 cites W2055348266 @default.
• W2907376823 cites W2086060360 @default.
• W2907376823 cites W2094160126 @default.
• W2907376823 cites W2097620275 @default.
• W2907376823 cites W2104818042 @default.
• W2907376823 cites W2105259666 @default.
• W2907376823 cites W2106928992 @default.
• W2907376823 cites W2133201432 @default.
• W2907376823 cites W2140283409 @default.
• W2907376823 cites W2146280097 @default.
• W2907376823 cites W2148999297 @default.
• W2907376823 cites W2207853596 @default.
• W2907376823 cites W2237608905 @default.
• W2907376823 cites W2321382767 @default.
• W2907376823 cites W2369038078 @default.
• W2907376823 cites W2537548903 @default.
• W2907376823 cites W2620029856 @default.
• W2907376823 cites W2767137920 @default.
• W2907376823 cites W2775803967 @default.
• W2907376823 cites W2802261508 @default.
• W2907376823 cites W2891199882 @default.
• W2907376823 doi "https://doi.org/10.1111/bjh.15741" @default.
• W2907376823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30592027" @default.
• W2907376823 hasPublicationYear "2018" @default.
• W2907376823 type Work @default.
• W2907376823 sameAs 2907376823 @default.
• W2907376823 citedByCount "12" @default.
• W2907376823 countsByYear W29073768232019 @default.
• W2907376823 countsByYear W29073768232020 @default.
• W2907376823 countsByYear W29073768232021 @default.
• W2907376823 countsByYear W29073768232022 @default.
• W2907376823 countsByYear W29073768232023 @default.
• W2907376823 crossrefType "journal-article" @default.
• W2907376823 hasAuthorship W2907376823A5008778599 @default.
• W2907376823 hasAuthorship W2907376823A5014979722 @default.
• W2907376823 hasAuthorship W2907376823A5017330007 @default.
• W2907376823 hasAuthorship W2907376823A5040054777 @default.
• W2907376823 hasAuthorship W2907376823A5054847681 @default.
• W2907376823 hasAuthorship W2907376823A5055488306 @default.
• W2907376823 hasAuthorship W2907376823A5057387418 @default.
• W2907376823 hasAuthorship W2907376823A5059148672 @default.
• W2907376823 hasAuthorship W2907376823A5060299777 @default.
• W2907376823 hasAuthorship W2907376823A5060345625 @default.
• W2907376823 hasAuthorship W2907376823A5061498879 @default.
• W2907376823 hasAuthorship W2907376823A5064132655 @default.
• W2907376823 hasAuthorship W2907376823A5076460303 @default.
• W2907376823 hasAuthorship W2907376823A5077518022 @default.
• W2907376823 hasBestOaLocation W29073768231 @default.
• W2907376823 hasConcept C126322002 @default.
• W2907376823 hasConcept C141071460 @default.
• W2907376823 hasConcept C2776063141 @default.
• W2907376823 hasConcept C2776364478 @default.
• W2907376823 hasConcept C2776694085 @default.
• W2907376823 hasConcept C2777132456 @default.
• W2907376823 hasConcept C2780964509 @default.
• W2907376823 hasConcept C71924100 @default.
• W2907376823 hasConcept C90924648 @default.
• W2907376823 hasConceptScore W2907376823C126322002 @default.
• W2907376823 hasConceptScore W2907376823C141071460 @default.
• W2907376823 hasConceptScore W2907376823C2776063141 @default.
• W2907376823 hasConceptScore W2907376823C2776364478 @default.
• W2907376823 hasConceptScore W2907376823C2776694085 @default.
• W2907376823 hasConceptScore W2907376823C2777132456 @default.
• W2907376823 hasConceptScore W2907376823C2780964509 @default.
• W2907376823 hasConceptScore W2907376823C71924100 @default.
• W2907376823 hasConceptScore W2907376823C90924648 @default.
• W2907376823 hasFunder F4320309086 @default.
• W2907376823 hasIssue "1" @default.
• W2907376823 hasLocation W29073768231 @default.
• W2907376823 hasLocation W29073768232 @default.
• W2907376823 hasOpenAccess W2907376823 @default.

• next